Tempus AI Reports Record Quarter - AI Data Business Grows 33% and Pharmaceutical Contracts Over $192.5 Million
Reading Time: 3 minutes
Cancer diagnostics booming: The oncology testing volume rises by 32% and strengthens the data foundation for AI. The AI data business grows by 33%, with new contracts amounting to up to $192.5 million. Moderna's success and around 23% short float open up additional price potential. Tempus AI (TEM) reports record revenues for Q3. Tempus combines genetic tests with patient data and AI to enhance cancer therapies and drug development. AI data business accelerates to 33% CEO Eric Lefkofsky reports a revenue increase of 33% for Data...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
